Education
About Us
Working with TipRanks
Follow Us
China Shineway Pharmaceutical Group Limited (HK:2877)
:2877
2877 Stock Chart & Stats
HK$8.58
HK$0.18(2.26%)
At close: 4:00 PM EST
HK$8.58
HK$0.18(2.26%)
Day’s Range― - ―
52-Week RangeHK$6.96 - HK$10.01
Previous CloseN/A
Volume914.00K
Average Volume (3M)1.29M
Market Cap
HK$7.40B
Enterprise Value-HK$239.60M
Total Cash (Recent Filing)HK$6.96B
Total Debt (Recent Filing)HK$341.34M
Price to Earnings (P/E)8.3
Beta0.57
Next Earnings
Mar 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.8%
Share Statistics
EPS (TTM)0.89
Shares Outstanding827,000,000
10 Day Avg. Volume1,790,900
30 Day Avg. Volume1,290,900
Financial Highlights & Ratios
PEG Ratio-0.61
Price to Book (P/B)0.92
Price to Sales (P/S)1.82
P/FCF Ratio8.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$10.04Price Target Upside17.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Robust Balance SheetLow leverage and a high equity ratio provide durable financial flexibility. Stable ROE indicates effective capital use, allowing the firm to fund R&D, support working capital and withstand industry cycles without immediate financing stress, strengthening long-term resilience.
Consistent Profitability MarginsSustained gross and net margins and solid operating profitability suggest structural pricing power or effective cost controls. This margin durability underpins cash generation capacity and helps absorb revenue volatility while funding strategic investment and distribution expansion.
Historically Positive Free Cash FlowA track record of positive operating and free cash flow indicates the business can convert earnings into cash, supporting dividends, capex and product development. Reliable cash generation is a durable buffer for execution and capital allocation choices.
Bears Say
Recent Revenue DeclineA ~21% year-over-year revenue decline signals a material drop in demand or lost share. Sustained revenue contraction can erode scale advantages, pressure fixed-cost absorption and constrain reinvestment capacity, making medium-term recovery and growth more challenging.
EPS ContractionA roughly 25% decline in EPS indicates reduced per-share profitability, which can weaken internal funding for R&D or dividends. Persistent EPS weakness may signal margin pressure or one-off hits that reduce financial flexibility and investor confidence over months.
Recent Cash Flow Reporting GapThe lack of reported operating cash flow in the latest period limits visibility on cash conversion and working capital trends. Even with prior positive FCF, missing recent data raises concern about cash sustainability and complicates reliable medium-term forecasting.
China Shineway Pharmaceutical Group Limited News
2877 FAQ
What was China Shineway Pharmaceutical Group Limited’s price range in the past 12 months?
China Shineway Pharmaceutical Group Limited lowest stock price was HK$6.96 and its highest was HK$10.01 in the past 12 months.
What is China Shineway Pharmaceutical Group Limited’s market cap?
China Shineway Pharmaceutical Group Limited’s market cap is HK$7.40B.
When is China Shineway Pharmaceutical Group Limited’s upcoming earnings report date?
China Shineway Pharmaceutical Group Limited’s upcoming earnings report date is Mar 31, 2026 which is in 38 days.
How were China Shineway Pharmaceutical Group Limited’s earnings last quarter?
China Shineway Pharmaceutical Group Limited released its earnings results on Aug 27, 2025. The company reported HK$0.885 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.885.
Is China Shineway Pharmaceutical Group Limited overvalued?
According to Wall Street analysts China Shineway Pharmaceutical Group Limited’s price is currently Undervalued.
Does China Shineway Pharmaceutical Group Limited pay dividends?
China Shineway Pharmaceutical Group Limited pays a Semiannually dividend of HK$0.12 which represents an annual dividend yield of 5.8%. See more information on China Shineway Pharmaceutical Group Limited dividends here
What is China Shineway Pharmaceutical Group Limited’s EPS estimate?
China Shineway Pharmaceutical Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China Shineway Pharmaceutical Group Limited have?
China Shineway Pharmaceutical Group Limited has 827,000,000 shares outstanding.
What happened to China Shineway Pharmaceutical Group Limited’s price movement after its last earnings report?
China Shineway Pharmaceutical Group Limited reported an EPS of HK$0.885 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 5.097%.
Which hedge fund is a major shareholder of China Shineway Pharmaceutical Group Limited?
Currently, no hedge funds are holding shares in HK:2877
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
China Shineway Pharmaceutical Group Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.07%
12-Months-Change
Fundamentals
Return on Equity
10.85%
Trailing 12-Months
Asset Growth
7.15%
Trailing 12-Months
Company Description
China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People's Republic of China and Hong Kong. The company offers modern Chinese medicines in the form of soft capsules, granules, and injections, as well as TCM Formula Granules in various therapeutic areas, including cardio-cerebrovascular, anti-viral, orthopedics, pediatrics, gynecology, and gastroenterology. It also trades in agricultural products. The company was incorporated in 2004 and is headquartered in Shijiazhuang, the People's Republic of China. China Shineway Pharmaceutical Group Limited is a subsidiary of Forway Investment Limited.
2877 Stock 12 Month Forecast
Average Price Target
HK$10.04
▲(17.02% Upside)
Technical Analysis
China Traditional Chinese Medicine Holdings Co
―
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H
―
Pak Fah Yeow International Limited
―
Jacobson Pharma Corporation Limited
―
Shandong Xinhua Pharmaceutical Company Limited Class H
―
Options Prices
Currently, No data available
---